Prevention of hypercalciuria and stone-forming propensity during prolonged bedrest by alendronate

Lisa A. Ruml, Susan K. Dubois, Marsha L. Roberts, Charles Y C Pak

Research output: Contribution to journalArticle

60 Citations (Scopus)

Abstract

The bone loss and hypercalciuria induced by immobilization or the decreased gravitational forces of space are well described. Using a model of bedrest immobilization, the ability of a potent aminobisphosphonate, alendronate, to avert hypercalciuria and stone-forming propensity was tested. Sixteen male subjects participated in a randomized, placebo-controlled trial in which they received either 20 mg of alendronate or placebo 2 weeks prior to and during 3 weeks of strict bedrest. Parameters of bone and calcium metabolism and urinary crystallization of stone-forming salts were measured before and at the end of bedrest. In the placebo group, bedrest increased urinary calcium (209 ± 47 to 267 ± 60 mg/day, p < 0.01) and the saturation of calcium phosphate. Before bedrest, the alendronate group had a significantly lower serum calcium (8.8 ± 0.4 vs. 9.6 ± 0.5 mg/dl, p < 0.01) and higher serum PTH (62.4 ± 33.1 vs. 23.1 ± 7.5 pg/ml, p < 0.01) compared with the placebo group. Moreover, the alendronate group had a lower urinary calcium (75 ± 41 mg/day) and saturation of calcium oxalate and calcium phosphate. These effects of alendronate were sustained during bedrest. Following bedrest in the alendronate group, urinary calcium rose to 121 ± 50 mg/day, a value less than that in the placebo group before or during bedrest. Similarly, urinary saturation of calcium oxalate and calcium phosphate rose with bedrest in the alendronate-treated patients but remained lower than values obtained in placebo-treated patients before or during bedrest. Alendronate inhibits bone mineral loss and averts the hypercalciuria and increased propensity for the crystallization of stone-forming calcium salts which occurs during 3 weeks of strict bedrest.

Original languageEnglish (US)
Pages (from-to)655-662
Number of pages8
JournalJournal of Bone and Mineral Research
Volume10
Issue number4
StatePublished - Apr 1995

Fingerprint

Hypercalciuria
Alendronate
Bed Rest
Placebos
Calcium
Calcium Oxalate
Crystallization
Bone and Bones
Immobilization
Salts
Urinary Calculi
Serum
Minerals
Randomized Controlled Trials

ASJC Scopus subject areas

  • Surgery

Cite this

Prevention of hypercalciuria and stone-forming propensity during prolonged bedrest by alendronate. / Ruml, Lisa A.; Dubois, Susan K.; Roberts, Marsha L.; Pak, Charles Y C.

In: Journal of Bone and Mineral Research, Vol. 10, No. 4, 04.1995, p. 655-662.

Research output: Contribution to journalArticle

@article{db5a0eb837724e2bb8e9ee48cc4176bf,
title = "Prevention of hypercalciuria and stone-forming propensity during prolonged bedrest by alendronate",
abstract = "The bone loss and hypercalciuria induced by immobilization or the decreased gravitational forces of space are well described. Using a model of bedrest immobilization, the ability of a potent aminobisphosphonate, alendronate, to avert hypercalciuria and stone-forming propensity was tested. Sixteen male subjects participated in a randomized, placebo-controlled trial in which they received either 20 mg of alendronate or placebo 2 weeks prior to and during 3 weeks of strict bedrest. Parameters of bone and calcium metabolism and urinary crystallization of stone-forming salts were measured before and at the end of bedrest. In the placebo group, bedrest increased urinary calcium (209 ± 47 to 267 ± 60 mg/day, p < 0.01) and the saturation of calcium phosphate. Before bedrest, the alendronate group had a significantly lower serum calcium (8.8 ± 0.4 vs. 9.6 ± 0.5 mg/dl, p < 0.01) and higher serum PTH (62.4 ± 33.1 vs. 23.1 ± 7.5 pg/ml, p < 0.01) compared with the placebo group. Moreover, the alendronate group had a lower urinary calcium (75 ± 41 mg/day) and saturation of calcium oxalate and calcium phosphate. These effects of alendronate were sustained during bedrest. Following bedrest in the alendronate group, urinary calcium rose to 121 ± 50 mg/day, a value less than that in the placebo group before or during bedrest. Similarly, urinary saturation of calcium oxalate and calcium phosphate rose with bedrest in the alendronate-treated patients but remained lower than values obtained in placebo-treated patients before or during bedrest. Alendronate inhibits bone mineral loss and averts the hypercalciuria and increased propensity for the crystallization of stone-forming calcium salts which occurs during 3 weeks of strict bedrest.",
author = "Ruml, {Lisa A.} and Dubois, {Susan K.} and Roberts, {Marsha L.} and Pak, {Charles Y C}",
year = "1995",
month = "4",
language = "English (US)",
volume = "10",
pages = "655--662",
journal = "Journal of Bone and Mineral Research",
issn = "0884-0431",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Prevention of hypercalciuria and stone-forming propensity during prolonged bedrest by alendronate

AU - Ruml, Lisa A.

AU - Dubois, Susan K.

AU - Roberts, Marsha L.

AU - Pak, Charles Y C

PY - 1995/4

Y1 - 1995/4

N2 - The bone loss and hypercalciuria induced by immobilization or the decreased gravitational forces of space are well described. Using a model of bedrest immobilization, the ability of a potent aminobisphosphonate, alendronate, to avert hypercalciuria and stone-forming propensity was tested. Sixteen male subjects participated in a randomized, placebo-controlled trial in which they received either 20 mg of alendronate or placebo 2 weeks prior to and during 3 weeks of strict bedrest. Parameters of bone and calcium metabolism and urinary crystallization of stone-forming salts were measured before and at the end of bedrest. In the placebo group, bedrest increased urinary calcium (209 ± 47 to 267 ± 60 mg/day, p < 0.01) and the saturation of calcium phosphate. Before bedrest, the alendronate group had a significantly lower serum calcium (8.8 ± 0.4 vs. 9.6 ± 0.5 mg/dl, p < 0.01) and higher serum PTH (62.4 ± 33.1 vs. 23.1 ± 7.5 pg/ml, p < 0.01) compared with the placebo group. Moreover, the alendronate group had a lower urinary calcium (75 ± 41 mg/day) and saturation of calcium oxalate and calcium phosphate. These effects of alendronate were sustained during bedrest. Following bedrest in the alendronate group, urinary calcium rose to 121 ± 50 mg/day, a value less than that in the placebo group before or during bedrest. Similarly, urinary saturation of calcium oxalate and calcium phosphate rose with bedrest in the alendronate-treated patients but remained lower than values obtained in placebo-treated patients before or during bedrest. Alendronate inhibits bone mineral loss and averts the hypercalciuria and increased propensity for the crystallization of stone-forming calcium salts which occurs during 3 weeks of strict bedrest.

AB - The bone loss and hypercalciuria induced by immobilization or the decreased gravitational forces of space are well described. Using a model of bedrest immobilization, the ability of a potent aminobisphosphonate, alendronate, to avert hypercalciuria and stone-forming propensity was tested. Sixteen male subjects participated in a randomized, placebo-controlled trial in which they received either 20 mg of alendronate or placebo 2 weeks prior to and during 3 weeks of strict bedrest. Parameters of bone and calcium metabolism and urinary crystallization of stone-forming salts were measured before and at the end of bedrest. In the placebo group, bedrest increased urinary calcium (209 ± 47 to 267 ± 60 mg/day, p < 0.01) and the saturation of calcium phosphate. Before bedrest, the alendronate group had a significantly lower serum calcium (8.8 ± 0.4 vs. 9.6 ± 0.5 mg/dl, p < 0.01) and higher serum PTH (62.4 ± 33.1 vs. 23.1 ± 7.5 pg/ml, p < 0.01) compared with the placebo group. Moreover, the alendronate group had a lower urinary calcium (75 ± 41 mg/day) and saturation of calcium oxalate and calcium phosphate. These effects of alendronate were sustained during bedrest. Following bedrest in the alendronate group, urinary calcium rose to 121 ± 50 mg/day, a value less than that in the placebo group before or during bedrest. Similarly, urinary saturation of calcium oxalate and calcium phosphate rose with bedrest in the alendronate-treated patients but remained lower than values obtained in placebo-treated patients before or during bedrest. Alendronate inhibits bone mineral loss and averts the hypercalciuria and increased propensity for the crystallization of stone-forming calcium salts which occurs during 3 weeks of strict bedrest.

UR - http://www.scopus.com/inward/record.url?scp=0028932304&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028932304&partnerID=8YFLogxK

M3 - Article

C2 - 7610938

AN - SCOPUS:0028932304

VL - 10

SP - 655

EP - 662

JO - Journal of Bone and Mineral Research

JF - Journal of Bone and Mineral Research

SN - 0884-0431

IS - 4

ER -